Ebola vaccine acceptance is high in the DRC, but provincial gaps remain wide
Ebola vaccine acceptance in the Democratic Republic of the Congo reached 79.0% in a national survey conducted between 2023 and 2024, a level that suggests substantial public readiness for future deployment if an outbreak demands rapid immunization. The findings come from a preprint analysis of 5,062 respondents and point to a country where familiarity with Ebola prevention appears relatively strong, yet far from uniform.
The most striking feature is not the national average. It is the spread between provinces. Acceptance ranged from 47.6% in Kongo Central to 92.1% in Tshuapa, a swing large enough to change how an emergency campaign would perform on the ground. In outbreak control, vaccine supply is only one part of the equation; community trust, local experience with Ebola, and health-system reach determine whether doses translate into coverage. Regional gaps can slow ring vaccination, complicate contact tracing efforts, and leave pockets of susceptibility inside a country that has repeatedly faced Ebola risk.
Provincial variation signals uneven readiness for outbreak response
The DRC has lived through Ebola for years, and that history likely shapes the pattern seen here. Where communities have had more direct exposure to response campaigns, treatment centers, or vaccination drives, acceptance may be easier to build. Where distrust, limited access, or weaker public-health communication persist, willingness can lag even when national awareness is high.
Healthcare workers stood out as the group with the highest acceptance. That finding matters because healthcare workers often act as both recipients and messengers during outbreak response. Their confidence in vaccination can influence patient counseling, community messaging, and the pace of vaccine uptake in facilities that may become early points of transmission. In a setting where Ebola can move quickly through households and health-care environments, the attitude of frontline staff can affect both protection and perception.
Acceptance alone does not equal immunization, but it is the first barrier that must fall. In the middle of an outbreak, delays in public agreement can be costly, especially when containment depends on quick deployment to contacts and high-risk communities.
Knowledge and acceptance moved in the same direction
The study also examined Ebola disease knowledge alongside vaccine acceptance, and the overall picture was encouraging. Nationally, disease knowledge was described as relatively strong, matching the elevated acceptance rate. That alignment fits a basic public-health principle: when people understand how a disease spreads, why it is dangerous, and how vaccination fits into prevention, willingness tends to rise.
Ebola is not an abstract threat in the DRC. It is a disease that has demanded repeated community engagement, and repeated exposure can improve awareness even when it does not eliminate hesitation. Knowledge about transmission, symptoms, and the purpose of vaccination can help reduce fear of the vaccine itself, especially in regions where rumors or misinformation may spread faster than official guidance. At the bedside and in the field, that means education remains a core intervention, not a secondary one.
Still, knowledge is unevenly distributed, and so is trust. The difference between one province and another may reflect prior outbreak experience, local health infrastructure, social networks, or the quality of communication between responders and residents. A national average can therefore obscure the communities most likely to be missed when the next campaign begins.
What the findings mean for Ebola rollout strategy
For future Ebola vaccination efforts in the DRC, the practical message is straightforward: national readiness is promising, but rollout plans must be province-specific. A uniform communication strategy may be too blunt for a country with such wide acceptance differences. Areas like Kongo Central, where acceptance was far lower, may require deeper community engagement, clearer local messaging, and stronger involvement of trusted health personnel and community leaders before vaccination campaigns begin.
By contrast, provinces with very high acceptance may be better positioned for rapid implementation, assuming logistics and supply can keep pace. Yet high acceptance should not lead to complacency. Ebola response depends on speed, and even receptive communities can face access barriers, staffing shortages, or delays in vaccine delivery. Public willingness is necessary, but it is only one element of operational success.
Because this is a preprint, the findings should be treated as an early read rather than final evidence. The study has not undergone peer review, and the available summary does not provide deeper detail on survey design, question wording, or the specific drivers behind provincial differences. Even so, the results are clinically and operationally relevant. They map where acceptance is strongest, where it is fragile, and where an outbreak response could encounter resistance before the first dose is given.
The data also reinforce a broader outbreak lesson: vaccination campaigns in Ebola-prone settings succeed when they are built around local trust, not just national policy. In the DRC, that trust appears substantial overall, but uneven enough that future planning cannot afford to ignore geography.